Mpox Vaccine Shows 58% Effectiveness in Ontario Study

A single dose of Bavarian Nordic's MVA-BN vaccine demonstrates moderate protection against mpox among high-risk groups.

A study in Ontario, Canada, found that a single dose of the MVA-BN vaccine provided 58% protection against mpox infection.
The study focused on men who have sex with men, who were most affected during the 2022 global mpox outbreak.
Researchers matched vaccinated and unvaccinated individuals by factors like age, location, and health status to estimate vaccine effectiveness.
The World Health Organization declared a second public health emergency over mpox due to rapid spread in Africa, with significant outbreaks in the Democratic Republic of Congo.
Experts emphasize the importance of achieving high vaccination coverage and suggest that a two-dose regimen could offer even greater protection.